Michael S. Brown - Jan 3, 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role: Director
Signature: /s/**Michael S. Brown
Stock symbol: REGN
Transactions as of: Jan 3, 2023
Transactions value $: $0
Form type: 4
Date filed: 1/5/2023, 03:21 PM
Previous filing: Nov 10, 2022
Next filing: Jan 10, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	REGN	Common Stock	Award	$0	+165	+15.25%	$0.00	1.25K	Jan 3, 2023	Direct	F1
holding	REGN	Common Stock						5K	Jan 3, 2023	by SLAT	F2
holding	REGN	Common Stock						6.66K	Jan 3, 2023	by Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	REGN	Non-Qualified Stock Option (right to buy)	Award	$0	+1.93K		$0.00	1.93K	Jan 3, 2023	Common Stock	1.93K	$725.89	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2	These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3	On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.